Login / Signup

Investigational drugs for the treatment of Zika virus infection: a preclinical and clinical update.

Yingshan HanThibault Mesplede
Published in: Expert opinion on investigational drugs (2018)
So far, 20 compounds have been tested in vivo and three in the clinical trials; progressing these compounds to the clinic is a challenge. Novel ZIKV inhibitors that target virus or host factors are urgently needed. Knowledge-driven drug repurposing, structure-based discovery, RNA interference, long noncoding RNAs, miRNAs, and peptide inhibitors may pave the way for the discovery of such novel agents.
Keyphrases
  • clinical trial
  • small molecule
  • high throughput
  • zika virus
  • healthcare
  • phase ii
  • primary care
  • randomized controlled trial
  • cell therapy
  • stem cells
  • open label
  • study protocol
  • replacement therapy
  • placebo controlled